The Club interviews Jesse Karmazin, CEO, to find out more about the trial, the FDA warning, and the relaunch
Biotechnology company focused on treating neurodegenerative and other age-related diseases
Aging is the dominant risk factor in degenerative diseases. Many of the pressing age-related and neurodegenerative diseases have a profound impact on patients and their caregivers, yet have very limited treatment options. Alkahest has embarked upon a simple but elegant approach to treat disorders of aging by capitalizing on the body’s own natural regulatory and communication mechanisms, leveraging the plasma proteome. The promise of this science, and the potential to make a difference to patients around the world, was the founding principle of Alkahest.
Alkahest’s therapeutic agents stem from a deep understanding of the changing plasma proteome in healthy aging and in age-related diseases. As we age, the majority of our proteins stay the same. But about 15% of our proteins change substantially as we age, or as we contend with disease. It’s these proteins, the chronokines, which inspire Alkahest science. By targeting chronokines, we develop clinical candidates that either increase or decrease the levels of circulating chronokines to promote innate and natural restorative biological processes or discourage pathological, degenerative processes in age-related diseases.
Visit website: http://www.alkahest.com/
Alkahest Blog Posts
People at Alkahest
Reason reports back from Age-Related Disease Therapeutics Summit 2023
Fight Aging! - 16-Jun-2023
Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few yearsRead more...
Super summary of 3rd Annual Longevity Therapeutics Summit
Lifespan.io (LEAF) - 16-Feb-2021
More and more companies making greater and greater progress - 2021 could be an exciting yearRead more...
LEAF interviews the Conboys about rejuvenating mice by diluting blood plasma
Lifespan.io (LEAF) - 16-Jun-2020
This could be a cheap first generation rejuvenation treatment - but wait for clinical trialsRead more...
Device by Alkahest to treat dialysis-associated dementia
Longevity Technology - 02-Jun-2020
With phase 2 study announced, hopes are up for end-stage renal disease sufferersRead more...
Longevity Leaders' latest report on how longevity is disrupting the world
Longevity Leaders (LSX) - 01-Jan-2020
An interesting collection of interviews and white-papers with industry leadersRead more...
Chronokines in young blood could be the cure for Alzheimer's
New Atlas - 06-Aug-2019
Plasma proteins to the rescue of good-old memories in Alzheimer'sRead more...
Oral treatment for wet age-related macular degeneration passes Phase 2a trials
CISION PR Newswire - 17-Dec-2018
Intriguing hint that this treatment may have potential for other age-related diseasesRead more...
Young blood as a key to living longer
Wired - 09-May-2018
GDF11 is a protein in the blood, which can stimulate cell growth and repairRead more...
Young blood does little to reverse Alzheimer’s in first test
Science Magazine - 01-Nov-2017
16 people with mild or moderate Alzheimer’s disease received weekly injections of young plasma. ...Read more...
Young blood antiaging trial raises questions
Science - 01-Aug-2016
Ambrosia (https://www.ambrosiaplasma.com/) young plasma trial is open to anyone 35 and older. Pa...Read more...